Telomerase is a ribonucleoprotein (RNAcontaining protein) complex composed of telomerase reverse transcriptase (TERT) and a telomerase RNA component (TERC), which assemble in a cell-cycle-dependent manner with several accessory factors to form the active holoenzyme 1 . Telomerase is a telomere-specific enzyme that extends telomeres, and its activity is required to overcome the end-replication problem, counteracting the progressive loss of telomeric DNA at the tips of linear chromosomes during DNA replication. In the absence of telomerase activity, telomere shortening would eventually result in the loss of genetic material and genetic catastrophe owing to breakage-fusion-bridge (BFB) cycles. These cycles involve breakage of unstable chromosome structures (for example, resulting from end-to-end fusion of telomere-dysfunctional chromosomes), which might be broken during mitosis, initiating repeated rounds of fusion and breakage, leading to genome instability 2 . Telomerase activity is maintained somatically in many animals, including pathway, provokes BFB cycles and enhances genomic instability, eventually promoting tumorigenesis [24] [25] [26] [27] . Telomerase activity is found in ~90% of human carcinomas and ~99% of urothelial carcinomas of the bladder (UCBs), supporting the idea that activation of telomerase is an essential requirement for the immortalization (unlimited proliferation capacity) of human cells 28, 29 . These observations led to the hypothesis that downregulation of telomerase activity is a mechanism that protects from tumorigenesis. In line with this hypothesis, telomerase activity is required for malignant conversion of primary human cells 30 . Tumours without telomerase maintain their telomere functionality via the alternative lengthening of telomeres (ALT) mechanism 31 . Stabilization of telomere length and functionality by ALT relies on homologous recombination of telomeric DNA between sister chromatids 32 . Recurrent mutations in the genes encoding death domain-associated protein 6 (DAXX) and the transcriptional regulator ATRX have been correlated with ALT occurrence and potentially contribute to ALT maintenance 33, 34 . Of note, evidence exists that telomerase activity supresses ALT, although the suppressive mechanism has not yet been identified [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . In a comprehensive analysis of 6,110 human tumour specimens from various cancer types, ALT was observed in only ~4% of samples 48 . Importantly, the prevalence of ALT varied between cancers. Most astrocytomas and sarcomas rely on ALT [48] [49] [50] , whereas telomerase activity is the primary mechanism for telomere maintenance in most other carcinomas 48, 51 . In UCB, the prevalence of ALT is low (~1%), indicating the importance of telomerase in this type of cancer 48 . Accumulating evidence shows that telomerase or its components have functions independent of telomere lengthening that affect many biological processes, including cell survival and apoptosis, DNA damage repair, mitochondrial function, cell adhesion and migration, and stem cell activity 34, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . These alternative functions can be independent of the enzymatic activity of telomerase 62 and can involve activation of the WNT-β-catenin signalling pathway the mouse [3] [4] [5] [6] [7] , but is downregulated during human development and cellular differentiation through transcriptional repression of TERT, which encodes the catalytic subunit [8] [9] [10] . In human adult nongermline tissues, TERT expression and telomerase activity are restricted to the stem or progenitor cell compartment of some tissues and can be activated in some cell types, such as lymphocytes, following proliferative stimulation 6, 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] . In the absence of sufficient telomerase activity, telomeres shorten in proliferating cells during ageing 20, 21 . Short, dysfunctional telomeres lose their capping function and activate DNA damage responses. When DNA damage checkpoints are intact, telomere shortening limits the proliferative capacity of human cells and serves as a tumour suppressor mechanism by activating cell cycle arrest and senescence once the replication limit of ~50 cell divisions (known as the Hayflick limit) is reached [20] [21] [22] [23] (Fig. 1) .
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Telomerase activity is maintained somatically in many animals, including pathway, provokes BFB cycles and enhances genomic instability, eventually promoting tumorigenesis [24] [25] [26] [27] . Telomerase activity is found in ~90% of human carcinomas and ~99% of urothelial carcinomas of the bladder (UCBs), supporting the idea that activation of telomerase is an essential requirement for the immortalization (unlimited proliferation capacity) of human cells 28, 29 . These observations led to the hypothesis that downregulation of telomerase activity is a mechanism that protects from tumorigenesis. In line with this hypothesis, telomerase activity is required for malignant conversion of primary human cells 30 . Tumours without telomerase maintain their telomere functionality via the alternative lengthening of telomeres (ALT) mechanism 31 . Stabilization of telomere length and functionality by ALT relies on homologous recombination of telomeric DNA between sister chromatids 32 . Recurrent mutations in the genes encoding death domain-associated protein 6 (DAXX) and the transcriptional regulator ATRX have been correlated with ALT occurrence and potentially contribute to ALT maintenance 33, 34 . Of note, evidence exists that telomerase activity supresses ALT, although the suppressive mechanism has not yet been identified [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . In a comprehensive analysis of 6,110 human tumour specimens from various cancer types, ALT was observed in only ~4% of samples 48 . Importantly, the prevalence of ALT varied between cancers. Most astrocytomas and sarcomas rely on ALT [48] [49] [50] , whereas telomerase activity is the primary mechanism for telomere maintenance in most other carcinomas 48, 51 . In UCB, the prevalence of ALT is low (~1%), indicating the importance of telomerase in this type of cancer 48 . Accumulating evidence shows that telomerase or its components have functions independent of telomere lengthening that affect many biological processes, including cell survival and apoptosis, DNA damage repair, mitochondrial function, cell adhesion and migration, and stem cell activity 34, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . These alternative functions can be independent of the enzymatic activity of telomerase 62 and can involve activation of the WNT-β-catenin signalling pathway the mouse [3] [4] [5] [6] [7] , but is downregulated during human development and cellular differentiation through transcriptional repression of TERT, which encodes the catalytic subunit [8] [9] [10] . In human adult nongermline tissues, TERT expression and telomerase activity are restricted to the stem or progenitor cell compartment of some tissues and can be activated in some cell types, such as lymphocytes, following proliferative stimulation 6, 7, [11] [12] [13] [14] [15] [16] [17] [18] [19] . In the absence of sufficient telomerase activity, telomeres shorten in proliferating cells during ageing 20, 21 . Short, dysfunctional telomeres lose their capping function and activate DNA damage responses. When DNA damage checkpoints are intact, telomere shortening limits the proliferative capacity of human cells and serves as a tumour suppressor mechanism by activating cell cycle arrest and senescence once the replication limit of ~50 cell divisions (known as the Hayflick limit) is reached [20] [21] [22] [23] (Fig. 1) .
These observations are supported by in vivo data that show that telomere dysfunction, in combination with a defective p53 Abstract | Telomerase activity imparts eukaryotic cells with unlimited proliferation capacity , one of the cancer hallmarks. Over 90% of human urothelial carcinoma of the bladder (UCB) tumours are positive for telomerase activity. Telomerase activation can occur through several mechanisms. Mutations in the core promoter region of the human telomerase reverse transcriptase gene (TERT) cause telomerase reactivation in 60-80% of UCBs, whereas the prevalence of these mutations is lower in urothelial cancers of other origins. TERT promoter mutations are the most frequent genetic alteration across all stages of UCB, indicating a strong selection pressure during neoplastic transformation. TERT promoter mutations could arise during regeneration of normal urothelium and, owing to consequential telomerase reactivation, might be the basis of UCB initiation, which represents a new model of urothelial cancer origination. In the future, TERT promoter mutations and telomerase activity might have diagnostic and therapeutic applications in UCB.
by TERT 52, 59 . However, the physiological relevance of the latter mechanism has been questioned57,63. Moreover, to modulate nuclear factor-κB (NF-κB)-dependent gene regulation 64 or ribosomal DNA transcription by RNA polymerase 1 (ReF.
65
), telomerase activity is required, but the presence of TERT alone is insufficient.
Data are emerging that show that telomeres can sense cellular stress conditions and induce cellular senescence to protect from tumorigenesis [66] [67] [68] . The cellular stress conditions can originate from chromosomal imbalances, such as aneuploidy, oxidative damage, or hyperproliferation signals resulting from oncogene activation 46, 66, 68, 69 . Telomeres are able to form G-quadruplex (G4) structures, which are four-stranded nucleic acid structures that have been observed in guanine-rich DNA regions 50, [70] [71] [72] . G4 structures preferentially form during replication and transcription and can be detected at telomeres 73 . The current understanding is that the G4 structures impose an obstacle to the replication machinery if not resolved properly 10, 74, 75 . Human telomeres contain 2,000-3,000 TTAGGG repetitions, which distinguishes telomeres from the rest of the genome and provides the basis for sensing genotoxic and oncogenic cell damage [76] [77] [78] [79] [80] [81] . Data show that the activity of specific helicases is required for the progression of the replication machinery to prevent replication fork stalling. Importantly, the ATP-dependent DNA helicase Pif1 requires telomerase to resolve G4 structures at telomeres in Saccharomyces cerevisiae 82 . These observations suggest that in the absence of telomerase, fork progression is impaired at telomeres owing to replication fork stalling, which can eventually lead to DNA double-strand breaks 76 . Importantly, the oncogene-induced senescence (OIS) or aneuploidy-induced senescence (AIS) response is independent of telomere length and can be reduced by telomerase activity 46, 66, 68, 83 . These data open a new perspective on the interplay of telomeres and telomerase in suppressing and promoting tumorigenesis 43, 69 . This new idea indicates that, in addition to the tumour-protective function induced by telomere shortening (Fig. 1) , telomeres can act as a barrier to tumour progression under conditions such as oncogene-induced hyperproliferation, genotoxic oxidative damage, or the presence of aneuploidyinducing mutations (Fig. 2) . Consequently, suppression of OIS or AIS by telomerase might enable telomerase-positive cells to acquire tumour-initiating mutations that would normally trigger telomere-mediated senescence in telomerase-negative cells 43 . How the activity of telomerase can suppress the telomere-length-independent protective function of telomeres is still unclear.
In this Perspectives, we examine new data showing a high prevalence of TERT promoter mutations in UCB, which occur early during tumorigenesis, indicating that the biology of the urothelium provides a selection pressure for this change. We consider the implications of telomerase activity for UCB cell survival in the context of telomere-length-dependent and telomere-length-independent roles of telomerase. We also specifically discuss the role of OIS and AIS abrogation in tumorigenesis. We present a new model of urothelial carcinogenesis that incorporates the role of telomerase activation and the potential of targeting telomerase as a therapeutic approach for UCB.
Telomerase in normal urothelium
Under physiological conditions, normal human urothelium is a long-lived, mitotically quiescent tissue with a low cell turnover rate but can develop a strong regenerative response and switch to a proliferative phenotype in response to damage [84] [85] [86] . In nonproliferating urothelium, telomerase is not detectable, but various reports have shown that normal human urothelial (NHU) cells, maintained in vitro as rapidly proliferating, nonimmortalized cell lines, have transient, low-level telomerase protein expression and enzyme activity 11, 13 . Whether telomerase becomes activated in human bladder urothelium in situ in response to physiological stress or regenerative conditions is not known. The regulatory mechanisms underlying the repression of telomerase activity in quiescent human urothelium and its activation during proliferation of NHU cells remain to be revealed. Transient, low-level telomerase expression and activity might be involved in physiological regeneration of the tissue, but stable overexpression of TERT or clonal expansion of cells with a mutated TERT promoter is required for the immortalization of NHU cells 13, 41, 87 . Of note, immortalization of NHU cells is dependent on the fully functional telomerase holoenzyme, as a carboxy-terminal-tagged TERT-HA (TERT protein fused to a short marker peptide sequence incorporating amino acids 98-106 of the human influenza haemagglutinin (HA) protein) restored enzymatic activity but was incapable of inducing immortalization 88 . Telomeraseimmortalized NHU cells remain genetically stable under standard growth conditions in vitro 13, 89 . However, when cultured under stress-imposing low-density conditions, genomic alterations that are similar to those seen in primary urothelial tumours can occur, such as loss of chromosomal region 2q 89 . In line with the extra-telomeric [155] [156] [157] . After a maximum number of cell replications (Hayflick limit), critically short telomeres induce replicative senescence in cells with a functional DDR , serving as a mechanism to protect from tumorigenesis. In DDR-deficient cells, overly short telomeres can result in genetic instabilities through repeated breakage-fusion-bridge cycles, which lead to cellular transformation. Transformed cells require telomerase activity to stabilize telomere functionality and avoid apoptosis, as well as for unlimited proliferation. Transformed cells in culture and human cancers usually reactivate telomerase or employ alternative lengthening of telomeres (ALT) as telomere maintenance mechanisms.
functions of telomerase, forced expression of TERT in NHU cells results in loss of differentiation capacity 13, 88 and changes in gene expression, including overexpression of the Polycomb repressor complex (PRC1 and PRC4) components BMI1 and sirtuin 1 (SIRT1) and downregulation of multiple PRC targets and genes associated with differentiation 88 .
TERT promoter mutations Telomerase activity, determined by the PCR-based telomerase repeated amplification protocol (known as TRAP) assay, has been found in 80-100% of UCBs but in only 2-5% of specimens from adjacent normal urothelium [90] [91] [92] . Similarly, telomerase activity was detectable in 62-100% of urinary samples from patients with UCB [90] [91] [92] . To date, only one study has implicated specific transcription factors in the regulation of telomerase activity in UCB cells 93 . Ectopic expression of the MYC proto-oncogene protein activated TERT transcription and telomerase activity, whereas its counterpart, mitotic spindle assembly checkpoint protein MAD1, had a repressive effect. Whether MYC and MAD1 affect telomerase activity in urothelial cells under physiological conditions is unknown.
Mutations in the promoter of the human TERT gene have been found in several cancer types, including UCB, and are the most common non-coding somatic mutations in cancer 58, [94] [95] [96] [97] [98] [99] . Of all UCB samples, 55-83% had TERT promoter mutations at one of the two positions responsible for maintaining telomerase activity in cancer cells 44, [100] [101] [102] . Nine benign proliferative urothelial lesions (cystitis, nephrogenic adenoma, and inverted papilloma) had only the wild-type TERT promoter sequence 44 . These observations indicate that urothelial cells with TERT promoter mutations arise de novo in a wild-type setting and that the mutation provides a selective advantage to the cell. The evidence further indicates that TERT promoter mutations have a tissuespecific role in urothelial tumorigenesis, as they have been reported in different histological variants of primary bladder cancer, including small-cell carcinoma 103 . In the case of bladder adenocarcinoma, TERT promoter mutations were restricted to non-enteric-type rather than enterictype adenocarcinomas (the latter typically being of urachal or metastatic colorectal derivation) 39, 44 . Nevertheless, other tissueregulatory factors might contribute to telomerase activity, as >90% of upper tract urothelial cancers (UTUCs) encompassing renal pelvic carcinomas and ureteric cancers have telomerase activity 104, 105 , but only 43% and 19% of these tumours contain the two common TERT promoter mutations, respectively 106 . These findings suggest that alternative regulatory mechanisms contribute to establishing telomerase activity in UTUC but not in UCB, possibly owing to their different embryological derivations. Similarly, a particularly high prevalence of TERT promoter mutations (100%) has been reported for micropapillary urothelial cancer 107 . The two key positions for mutations in the TERT promoter are C228T and C250T (located at positions -124 and -146, respectively, relative to the ATG start codon) 98, [108] [109] [110] . Mutations in the TERT coding region are rare (frequency < 0.5%) 111 , but TERT promoter mutations occur in 60-80% of UCB samples, and the C228T and C250T mutations together account for 99% of these mutations. Convincing experimental evidence exists that both these mutations create novel binding sites for the heterotetrameric GA-binding protein (GABP) transcription factor, resulting in increased transcription of TERT and activation of telomerase 95, 101, 112 .
TERT mutations as prognostic markers Several studies have examined potential associations of TERT promoter mutations with UCB stage and grade. The studies report TERT promoter mutations in 59-79% (mean 70%) of UCBs, irrespective of tumour stage or grade 44, 98, 100, 113, 114 . One team of researchers assessed disease-specific survival in correlation with TERT promoter mutations and TERT mRNA levels in two independent cohorts of chemotherapy-naive patients (n = 35 and n = 87) and found that the abundance of TERT mRNA, rather than promoter mutation itself, correlated strongly with reduced disease-specific survival 102 . They further showed that TERT promoter mutations correlated with TERT mRNA abundance, telomerase activity, and telomere length, whereas telomerase-positive cells without TERT promoter mutations did not show these correlations. These observations might also explain the results obtained by another group who analysed urine samples of 230 patients with non-muscle-invasive bladder cancer (NMIBC) and 25 samples of patients with muscle-invasive bladder cancer (MIBC). They found that TERT promoter mutations were the most common aberration detected (52% of all samples) and showed significant associations between TERT promoter mutations and progression of NMIBC to MIBC (9 of 110 patients with TERT promoter mutation but only 1 of 109 patients without TERT promoter mutation progressed; P = 0.01). The presence of TERT promoter mutation was also significantly associated with NMIBC risk groups (P < 0.0001) 40 . Also of note, TERT promoter mutations were found to be associated with distant metastases in UTUC 106 , suggesting a selective advantage. In another study, sequencing of 76 urothelial carcinomas demonstrated TERT promoter mutations ) with a telomerase-reactivating TERT promoter mutation, the mutated cell can continue to proliferate. During continued proliferation, the cell accumulates additional mutations, eventually leading to transformation and cancer.
in both low-grade and high-grade UCB, as well as in flat and papillary lesions 115 . The same mutations were also detectable in urine and were strongly associated with UCB recurrence, providing a potential prognostic urinary biomarker. The potential to use TERT promoter mutations as a urinary biomarker to detect UCB was explored in a prospective study using samples from 475 patients, which showed that TERT promoter mutations had the highest sensitivity (81.8%) but also the lowest specificity (83.5%) to detect UCB (tested markers included TERT, FGFR3, SALL3, ONECUT2, CCNA1, BCL2, EOMES, and VIM) 116 .
TERT mutations and cancer initiation
Mutations that occur in adult stem cells are believed to have the largest effect on the mutational load of tissues owing to their capacity to give rise to all descendant cells in a tissue 117, 118 . Stem cell tracing experiments support this idea by showing that mutations that occur in stem cells are efficient cancer drivers, whereas the same mutations in differentiated cells fail to initiate cancer 119 . This view is supported by reports showing the accumulation of mutations in adult stem cells during life 37 . However, stem cells are rare and considered to divide infrequently, giving rise to a rapidly expanding suprabasal compartment of highly proliferating transitamplifying cells. In the past 5 years, an alternative cancer cell origin theory has emerged in favour of the transit-amplifying cell population [120] [121] [122] . This concept takes into account that mutation rates are increased in replicating cells 120 and that most heritable mutations occur in the transit-amplifying cells that constitute the majority of the stem or progenitor cell pool, rather than in the small number of rarely dividing adult stem cells (Fig. 3) .
The presence and nature of stem cells in human bladder urothelium is still under debate, but studies in animal models indicate that subpopulations of bladder urothelial cells (positive for either tumour protein p63, sonic hedgehog protein (SHH), cytokeratin 5 (KRT5), or KRT14) confer self-renewal ability and are considered to constitute the stem or progenitor cell population of the bladder epithelium [123] [124] [125] [126] . In one study in mice, KRT14-positive cells, which are a subpopulation of KRT5-positive cells, gave rise to all cell types of the urothelium during injuryinduced regeneration and were regarded as the cells of origin of urothelial cancer 127 . By contrast, studies with mouse and pig urothelial cells suggest that both the basal and intermediate cells can contribute to the regenerative potential of the bladder urothelium, indicating that a stringent requirement for a stem cell population does not apply to bladder urothelium 86, 128 . These studies might be helpful in understanding the contribution of different cell types to bladder regeneration and cancer in different species but, unlike in human somatic tissues, telomerase is constitutively expressed in all mouse tissues 5, 6 . Thus, irrespective of the stem cell debate, the common occurrence of TERT promoter mutations that result in constitutive telomerase activity demonstrates the critical importance of this tumour suppressor in human UCB.
In a series of experiments performed on cell fractions enriched from isolated human UCB and normal urothelium samples, one team of researchers located TERT promoter mutations (primarily the C228T mutation) in basal cells (defined as being positive for CD44 and KRT5 and negative for KRT20) from UCB samples but not in those from normal urothelium (normal bladder basal cells (NBBCs)) 129 . Furthermore, these TERT promoter mutations were enriched in basal cells compared with non-basal bladder cancer cells. Importantly, restoring the C228T mutation to the wild-type sequence abolished the tumour-forming ability of bladder cancer cells in mouse xenograft experiments. Conversely, basal urothelial cells isolated from adjacent noncancerous bladder tissue expressed wild-type TERT and developed xenograft tumours in nude mice only when the C228T mutation was introduced at the genomic level, suggesting that TERT promoter mutation is a crucial event in the malignant transformation of human urothelium 129 . Pending formal demonstration, these data suggest that tumour-adjacent normal bladder urothelial cells have accumulated cancer-initiating genetic mutations that are not sufficient for malignant transformation by themselves but require activation of telomerase as the tumour-promoting step; of note, telomerase is not an oncogene by itself 130 . , potentially through downregulation of components of Polycomb repressor complex targets and genes associated with differentiation 88 . Cells with TERT mutations show sustained proliferation and can accumulate additional mutations (red flash icons) that promote malignant transformation. Mutation rates are higher in proliferating cells during replication than in nonproliferating differentiated cells 120 . Usually , most of the mutations are repaired or the cell with an oncogenic mutation and/or aneuploidy-inducing mutation enters senescence or is cleared by apoptosis. New data indicate that telomerase can suppress the induction of oncogeneinduced senescence or aneuploidy-induced senescence, respectively. Thus, TERT promoter mutations leading to activation of telomerase are likely to be the first mutations in proliferating basal cells that are devoid of telomerase activity. Whether telomerase also suppresses apoptosis is not well documented and remains to be clarified.
One further observation was that human NBBCs had no telomerase activity 129 . This feature differentiates NBBCs from intestinal stem cells and haematopoietic stem cells, which have constitutive telomerase activity. Consistent with the reports showing transient activation of telomerase in normal urothelial cells in culture 11, 13 , it seems plausible that NBBCs might be able to upregulate telomerase expression transiently in response to regenerative signals.
The implications of these data in the context of cancer-initiating cells require further clarification. The presence or absence of telomerase activity in resting NBBCs has to be demonstrated unequivocally, but current data indicate that these cells are telomerase-negative 129 .
In the absence of telomerase, harmful cancer-initiating mutations, such as oncogene activation (leading to OIS) or aneuploidy-inducing mutations (leading to AIS), would interfere with cell fitness and would induce premature senescence as a tumour-suppressor mechanism (Fig. 2) . We therefore suggest that, in UCB, the first tumour-initiating mutation is likely to be a telomerase re-activating mutation (for example, in the TERT promoter) in cells that have been activated for proliferation (Fig. 3) . Telomerase activity could then facilitate the survival of cells with secondary cancer-promoting mutations and prevent entry into cellular senescence. The fact that TERT promoter mutations occur preferentially or exclusively in tissues that have low or absent telomerase activity in their nonproliferating cells, such as bladder urothelium 96, 97 , supports this hypothesis. In fact, high rates of TERT promoter mutations have been observed in liver cancer, and the liver is another mitotically quiescent, highly regenerative tissue in which the identity of stem cells has not been clarified. Human hepatocytes are telomerase-negative in the resting state but can upregulate telomerase activity following stimulatory signals during regeneration 7 . In a study published in 2015, researchers introduced the common TERT promoter mutations into human embryonic stem cells (hESCs) and demonstrated that these mutations prevented downregulation of the TERT promoter and telomerase activity during differentiation of these mutant hESCs but not during the differentiation of wild-type hESCs 131 . These data suggest that TERT promoter mutations that occur in stem or progenitor cells prevent differentiation and the shortening of telomeres. By contrast, the absence of TERT promoter mutations in cancers arising from highly proliferative tissues with a stem cell compartment 38, 132 might be explained by the inherently high telomerase activity of their stem cells 35 . This hypothesis assumes that, if the stem cells are the origin of TERT promoter mutations, the mutation rate of the TERT promoter would be expected to occur at a similar rate in all tissues.
In summary, we hypothesize that TERT promoter mutations occur in telomerase-negative cells that are activated for proliferation on demand. Induction of telomerase activity in human tissues through injury and physiological stimuli has been shown [133] [134] [135] [136] . In addition, the human TERT promoter is activated in response to liver injury in a mouse model carrying a human TERT promoter fragment in front of the lacZ reporter gene 7 . In the bladder urothelium, it seems plausible to assume that TERT promoter mutations occur in proliferating cells that have transiently activated telomerase in response to injury, which is in line with the alternative model of transitamplifying cells as the cancer-initiating cells with the highest mutation rate (Fig. 3) . Of note, no TERT promoter mutations were found in a carcinogen-induced mouse bladder cancer model that otherwise shows a mutational signature similar to that of human bladder cancer (for example, Trp53 mutations) and recapitulates the molecular alterations of human MIBC 137 . The lack of TERT promoter mutations in this mouse model can be explained by the constitutive TERT expression (and constitutive telomerase activity) in mouse tissues [3] [4] [5] [6] [7] . In light of the novel findings that telomerase can suppress senescence induction caused by genome instability (AIS) or OIS 67, 68 , we extend this model to suggest that TERT promoter mutations are likely to be the first tumour-initiating mutations in tissues that lack telomerase activity in their nonproliferating cells.
Interestingly, the lack of TERT promoter mutations in primary bladder adenocarcinoma suggests that this entity might have a different origin of cancer 138 . This idea might also support the conclusion regarding the cell type of origin for UTUC, in which a low rate of TERT promoter mutations is observed despite activation of telomerase in the vast majority of UTUCs [104] [105] [106] . In urothelial tumours (of any origin) that lack TERT promoter mutations, whether telomerase reactivation is a late event caused by telomere-dysfunctioninitiated genome instability or whether telomerase reactivation occurs early during cellular transformation, potentially promoting tumorigenesis by telomerelength-independent mechanisms, is still unclear. Of note, telomerase reactivation is not the primary tumour-initiating event in these tumour types but might result from loss of negative regulatory factors that suppress TERT promoter activity in normal cells and/or from an aberrant, increased expression of factors that positively regulate TERT expression 43 .
Opportunities in diagnosis and therapy
The high frequency of specific TERT promoter mutations across all UCB grades and stages and their absence from adjacent histologically normal urothelium indicates an important function in both neoplastic transformation and maintenance of UCB 44, 98, 100, 113, 114 . This finding has led several groups to examine whether detection of TERT promoter mutations could be a urinary marker for bladder cancer detection 100 . A noninvasive liquid biopsy approach is highly attractive 139 , as it might replace costly long-term cystoscopic surveillance for recurrence of low-grade noninvasive UCB and function as a screening tool for detecting UCB (particularly early detection of MIBC) in high-risk groups 116, 140 . TERT promoter mutation detected in urine might be indicative of not only UCB but also UTUC or renal cell carcinoma, although TERT promoter mutation rates in these tumour types are lower than in UCB 106, 141 . One retrospective study has indicated that urinary TERT promoter mutation detection is not prognostic of UCB clinical outcome 100 , but it might be a suitable marker for monitoring disease recurrence 102 . However, large prospective studies are awaited to determine the value of any clinical test on the basis of TERT promoter mutation detection 142 . The presence of telomerase activity in most human cancers, along with mouse model data indicating its requirement for tumour progression, has inspired the development of telomerase inhibitors and their testing in preclinical studies 19, [143] [144] [145] [146] [147] [148] . UCB is a good candidate for telomerasebased therapies, as most UCBs are telomerase-positive. The first generation of inhibitors targeted telomerase activity itself, for example, by stabilizing the G4 structure 45 . The first of these inhibitors to enter phase II trials, imetelstat, showed promising clinical activity against myeloproliferative neoplasms rather than solid tumours [149] [150] [151] . This finding indicates the need to identify novel targets on the basis of the specific molecular understanding of telomeric and cancer-associated extra-telomeric functions of telomerase in UCB 34 . Alternative targeting of telomerase activity has been investigated with the nucleoside analogue 6-thio-2′-deoxyguanosine. This compound is a telomerase substrate precursor that becomes incorporated into telomeric DNA by telomerase during DNA replication, resulting in rapid telomere deprotection and apoptosis in telomerase-positive cancer cell lines originating from the colon (HCT116), lung (A549), or liver (HCC15), whereas telomerase-negative cell lines, including primary human fibroblasts (BJ) or telomerase-negative but ALT-positive immortal human fibroblasts (AV13), were resistant to the treatment 152, 153 . The protein components of the telomereprotective shelterin complex, a complex of six protein components (telomeric repeat-binding factor 1 (TERF1), TERF2, TRF2-interacting protein 1 (TERF2IP), TERF1-interacting nuclear factor 2 (TINF2), protection of telomeres protein 1 (POT1), and tripeptidyl-peptidase 1 (TPP1)) that specifically associate with telomeres, also offer alternative targets. These shelterin components protect telomere length and structure, partly by regulating telomerase activity and access to the telomeric DNA 154 . In cells with dysfunctional telomeres, chromosome ends are no longer protected efficiently by the shelterin components. These unprotected telomeres resemble chromosome breaks and activate the DNA damage response [155] [156] [157] . Furthermore, they are prone to degradation by exonucleases and lose their capping function to protect from end-to-end fusions or loss of genetic material. This process of telomereuncapping and deprotection can be induced by progressive telomere shortening in the absence of sufficient telomerase activity as well as by mutant or genetically modified shelterin proteins, resulting in activation of p53-dependent senescence and/or apoptotic responses 158 . PINX1 is of particular relevance in UCB, as it encodes a shelterin-recruited telomerase-regulatory protein and displays single-nucleotide polymorphisms that are associated with substantially reduced bladder cancer risk [159] [160] [161] . Hence, specific targeting of shelterin components or telomerase-associated proteins could be a useful strategy to modulate telomerase activity for UCB therapy.
In addition, evidence of noncanonical, extra-telomeric functions of telomerase and their utility as treatment targets is accumulating. As an example, eribulin, an anticancer drug that interferes with microtubule elongation, inhibits the RNAdependent RNA polymerase activity of telomerase 162 . Further understanding of the noncanonical roles of telomerase holds the potential for developing new cancer-specific therapeutics.
As the prevalence of ALT is low or absent in UCB, telomerase targeting can be considered a promising first-line strategy. However, secondary activation of ALT is a potential drawback of any telomerase-inhibiting therapy. Studies in a lymphoma-prone mouse model have shown that deletion of telomerase in tumours provokes activation of ALT in cancer cells as an adaptive response 163 . Whether ALT activation is of concern in human UCB is not yet clear, but research on the potential telomere-length-independent functions of telomerase gives reason to hope that telomerase inhibition might result in a telomere-length-independent senescence response that protects from tumorigenesis without activating ALT. In the meantime, ALT itself remains a potential target.
Conclusions
The high prevalence of telomerase activity in UCB and identification of two hotspot mutations within the TERT promoter region as the most frequent genetic alteration across all disease stages indicate a very strong selection pressure for telomerase activation during neoplastic transformation. Three conclusions can be drawn from our current understanding of telomerase function in the initiation and maintenance of UCB and provide prospects for developing cancer-specific therapies. First, TERT promoter mutations resulting in telomerase overactivity occur in telomerase-negative cells that reside in tissues without a welldefined telomerase-positive stem cell compartment. Notably, a potential transient function of telomerase in the regenerative response of urothelium remains an open question. Second, the observations that TERT promoter mutations are detectable in all stages of UCB, but not in overtly normal urothelium, indicate that telomerase activation provides a survival advantage during the initial stages of urothelial tumorigenesis. This notion is in line with the noncanonical functions of telomerase in the abrogation of AIS and/or suppression of OIS. Thus, in the absence of telomerase, harmful cancer-initiating mutations, such as oncogene activation or aneuploidy-inducing mutations, would interfere with cell fitness and induce premature senescence as a tumour suppressor mechanism through sensing by telomeres. By contrast, urothelial cells that acquire telomerase-activating TERT promoter mutations obtain a survival advantage. This insight might lead to new strategies for cancer therapy. Third, on the basis of the alternative cancer cell origin theory that suggests that the transitamplifying cells are the cells of origin of cancer 121, 122 , TERT mutations should occur in proliferating rather than in mitotically quiescent urothelial cells. These cells with TERT promoter mutations are probably the cancer-initiating cells, which then accumulate additional oncogenic mutations during UCB progression. Consequently, detection of TERT promoter mutations in body fluids might be an early marker of UCB and potentially a marker for early cancer therapy targeting telomerase.
